Home >> Services >> All Other
 Hereditary Angioedema Therapeutic Market
Posted on : Wednesday, 29 January, 2020  08:39
Location : Františkovy Lázně, Karlovarský kraj
Phone Number# : ---
 




Hereditary Angioedema Therapeutic Market size was valued at USD xx million in 2018 and is expected to reach at USD xx million by 2026 at a CAGR of xx% over forecast period 2019-2026.

Global Hereditary Angioedema Therapeutic Market

Increasing cases of hereditary angioedema (HAE) globally is a mainly driving the Hereditary Angioedema Therapeutic market. According to the National Organization for Rare Disorders (NORD), about 1-9 people per 100,000 population are affected by the condition. The actual number of individuals with the condition are significantly higher due to under-reporting and misdiagnosis.

In 2018, there were approximately 422,700 prevalent cases of hereditary angioedema worldwide, and forecasts that number to increase to XX K prevalent cases by 2026. This increasing cases of hereditary angioedema (HAE) is driving the hereditary angioedema (HAE) therapeutics market.

Lack of awareness about HAE International (HAE), an international hereditary angioedema patient organization, is a major reason for misdiagnosis, which in turn, leads to inadequate treatment being provided to patients.

The hereditary angioedema market is segmented into such as drug class, route of administration, by treatment type, and by region. By drug class market is further segmented into four other categories such as kallikrein inhibitor, selective bradykinin B2 receptor antagonist, C1 esterase inhibitor, and others. C1 esterase inhibitor segment is expected to exhibit highest market share at a CAGR of XX% over forecast period.

By geography, hereditary angioedema market is segmented into APAC, North America, Europe, MEA& Africa and Latin America. North America accounted for a leading share in the market in terms of revenue in 2018 owing to new product launches by major players, better reimbursement scenario, and a well-developed healthcare infrastructure. Growing patient awareness levels, coupled with launch of novel therapies for hereditary angioedema management, is expected to drive the market in the region.

Key players operating in hereditary angioedema market are BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Pharming Group N.V., CSL Limited, Shire Plc., Attune Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., and KalVista Pharmaceuticals, Inc. These players are entering into distribution agreements in order to increase their market share boost and their presence across different geographies.


  
  
  In this Ad : Offering a service
  Posted By: An Individual
  It is ok to contact this poster with commercial interests.



Home Browse Cities Sitemap Privacy Policy Disclaimer Contact Us

Copyright © 2014 Unolist LLC. All rights reserved.